Mostrar el registro sencillo del ítem

Preclinical evaluation of Imatinib does not support its use as an antiviral drug against SARS-CoV-2

dc.rights.licenseopenen_US
dc.contributor.authorTOURET, Franck
dc.contributor.authorDRIOUICH, Jean-Selim
dc.contributor.authorCOCHIN, Maxime
dc.contributor.authorPETIT, Paul Remi
dc.contributor.authorGILLES, Magali
dc.contributor.authorBARTHELEMY, Karine
dc.contributor.authorMOUREAU, Gregory
hal.structure.identifierActions for OnCogenesis understanding and Target Identification in ONcology [ACTION]
dc.contributor.authorMAHON, Francois-Xavier
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorMALVY, Denis
ORCID: 0000-0003-1948-9355
IDREF: 148480993
dc.contributor.authorSOLAS, Caroline
dc.contributor.authorDE LAMBALLERIE, Xavier
dc.contributor.authorNOUGAIREDE, Antoine
dc.date.accessioned2021-08-30T09:51:11Z
dc.date.available2021-08-30T09:51:11Z
dc.date.issued2021-07-12
dc.identifier.issn0166-3542en_US
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/110250
dc.description.abstractEnFollowing the emergence of SARS-CoV-2, the search for an effective and rapidly available treatment was initiated worldwide based on repurposing of available drugs. Previous reports described the antiviral activity of certain tyrosine kinase inhibitors (TKIs) targeting the Abelson kinase 2 against pathogenic coronaviruses. Imatinib, one of them, has more than twenty years of safe utilization for the treatment of hematological malignancies. In this context, Imatinib was rapidly evaluated in clinical trials against Covid-19. Here, we present the pre-clinical evaluation of imatinib in multiple models. Our results indicated that imatinib and another TKI, the masitinib, exhibit an antiviral activity in VeroE6 cells. However, imatinib was inactive in a reconstructed bronchial human airway epithelium model. In vivo, imatinib therapy failed to impair SARS-CoV-2 replication in a golden Syrian hamster model despite high concentrations in plasma and in the lung. Overall, these results do not support the use of imatinib and similar TKIs as antivirals in the treatment of Covid-19.
dc.language.isoENen_US
dc.rightsAttribution-NonCommercial-NoDerivs 3.0 United States*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/3.0/us/*
dc.subject.enSARS-CoV-2
dc.subject.enCovid-19
dc.subject.enCoronavirus
dc.subject.enAntivirals
dc.subject.enTyrosine kinase inhibitor
dc.subject.enImatinib
dc.title.enPreclinical evaluation of Imatinib does not support its use as an antiviral drug against SARS-CoV-2
dc.typeArticle de revueen_US
dc.identifier.doi10.1016/j.antiviral.2021.105137en_US
dc.subject.halSciences du Vivant [q-bio]/Santé publique et épidémiologieen_US
dc.identifier.pubmed34265358en_US
bordeaux.journalAntiviral Researchen_US
bordeaux.page105137en_US
bordeaux.volume193en_US
bordeaux.hal.laboratoriesBordeaux Population Health Research Center (BPH) - UMR 1219en_US
bordeaux.institutionUniversité de Bordeauxen_US
bordeaux.institutionINSERMen_US
bordeaux.teamIDLICen_US
bordeaux.peerReviewedouien_US
bordeaux.inpressnonen_US
bordeaux.identifier.funderIDInstitut National de la Santé et de la Recherche Médicaleen_US
bordeaux.identifier.funderIDFondation de Franceen_US
hal.identifierhal-03328717
hal.version1
hal.date.transferred2021-08-30T09:51:16Z
hal.exporttrue
dc.rights.ccPas de Licence CCen_US
bordeaux.COinSctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Antiviral%20Research&rft.date=2021-07-12&rft.volume=193&rft.spage=105137&rft.epage=105137&rft.eissn=0166-3542&rft.issn=0166-3542&rft.au=TOURET,%20Franck&DRIOUICH,%20Jean-Selim&COCHIN,%20Maxime&PETIT,%20Paul%20Remi&GILLES,%20Magali&rft.genre=article


Archivos en el ítem

Thumbnail
Nombre:
BPH_AR_2021_Touret.pdf
Tamaño:
2.514Mb
Formato:
PDF
Ver/Abrir
Thumbnail
Nombre:
license_rdf
Tamaño:
811bytes
Formato:
application/rdf+xml
Ver/Abrir

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem